CLLS logo

CLLS Cellectis S.A.

NASDAQ Global Market · Biotechnology · Healthcare

$0.92
-0.08 (-7.89%)

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: The…

Market Cap: $92.76Mwww.cellectis.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
50
5 mentions
—
60d
44
8 mentions
—
90d
42
15 mentions
—
news: 15

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 3Sell 2Strong Sell 0
Avg price target$2.15+133.5%
Low $1.3Median $2.15High $3
Current Consensus

Revenue

$5.44M-31.94%
$139.6K$16.80M$33.47M$50.13M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.76
$-1.28–$-0.45
1 analysts
FY2026
$-1.21
$-2.05–$-0.73
1 analysts
FY2027
$-0.86
$-1.47–$-0.52
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Andre Choulika
Sector
Healthcare
Industry
Biotechnology
Employees
229
Beta
3.20
Country
FR
Piotroski score
2 / 9 (Weak)
Altman Z-score
-4.00
www.cellectis.com